FURTHER EVIDENCE THAT NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS A THROMBOPHILIC STATE: PLASMINOGEN ACTIVATOR INHIBITOR ONE LEVELS ARE SIGNIFICANTLY ELEVATED IN LIVER TRANSPLANT CANDIDATES WITH DECOMPENSATED NONALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS

被引：0
|
作者：
Stine, Jonathan [1 ]
Baragona, Allison [2 ]
Hummer, Breianna [1 ]
Rivas, Gloriany [1 ]
Bezinover, Dmitri [3 ]
Kadry, Zakiyah [4 ]
机构：
[1] Penn State Univ, Milton S Hershey Med Ctr, Div Gastroenterol & Hepatol, Dept Med, University Pk, PA 16802 USA
[2] Penn State Univ, Milton S Hershey Med Ctr, Gastroenterol & Hepatol, Dept Med, University Pk, PA 16802 USA
[3] Penn State Univ, Milton S Hershey Med Ctr, Dept Anesthesia, University Pk, PA 16802 USA
[4] Penn State Univ, University Pk, PA 16802 USA
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2290
引用
收藏
页码：1346A / 1346A
页数：1
相关论文
共 50 条
  • [1] Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
    Rivas, Gloriany
    Hummer-Bair, Breianna
    Bezinover, Dmitri
    Kadry, Zakiyah
    Stine, Jonathan
    BMJ OPEN GASTROENTEROLOGY, 2021, 8 (01):
  • [2] Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
    Duarte, Sebastiao M. B.
    Stefano, Jose Tadeu
    Oliveira, Claudia P.
    ANNALS OF HEPATOLOGY, 2019, 18 (03) : 416 - 421
  • [3] Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH)
    Ota, Tsuguhito
    CAROTENOIDS: BIOSYNTHETIC AND BIOFUNCTIONAL APPROACHES, 2021, 1261 : 223 - 229
  • [4] Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
    Drescher, Hannah K.
    Weiskirchen, Sabine
    Weiskirchen, Ralf
    CELLS, 2019, 8 (08)
  • [5] Predictive Factors for Nonalcoholic Steatohepatitis (NASH) in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
    Fierbinteanu-Braticevici, Carmen
    Baicus, Cristian
    Tribus, Laura
    Papacocea, Raluca
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2011, 20 (02) : 153 - 159
  • [6] Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in Patients with Morbid Obesity
    Manno, Emilio
    OBESITY SURGERY, 2010, 20 (06) : 811 - 811
  • [7] Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)
    Gerhardt, Florian
    Petroff, David
    Blank, Valentin
    Boehlig, Albrecht
    van Boemmel, Florian
    Wittekind, Christian
    Berg, Thomas
    Karlas, Thomas
    Wiegand, Johannes
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 706 - 711
  • [8] Vitamin D deficiency and development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
    Bril, Fernando
    Lomonaco, Romina
    Orsak, Beverly
    Ortiz-Lopez, Carolina
    Biernacki, Diane
    Klaczak, Ashley
    Chang, Zhi
    Hardies, Jean
    Cusi, Kenneth
    HEPATOLOGY, 2013, 58 : 522A - 522A
  • [9] Variants of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with rapidly progressive course
    Tan, V.
    Merriman, R.
    Ferrell, L.
    LABORATORY INVESTIGATION, 2008, 88 : 317A - 317A
  • [10] The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
    Younossi, Zobair M.
    Golabi, Pegah
    Paik, James M.
    Henry, Austin
    Van Dongen, Catherine
    Henry, Linda
    HEPATOLOGY, 2023, 77 (04) : 1335 - 1347
12345